154 related articles for article (PubMed ID: 33709175)
41. Surgical Management of Early-Stage Esophageal Adenocarcinoma Based on Lymph Node Metastasis Risk.
Newton AD; Predina JD; Xia L; Roses RE; Karakousis GC; Dempsey DT; Williams NN; Kucharczuk JC; Singhal S
Ann Surg Oncol; 2018 Jan; 25(1):318-325. PubMed ID: 29147928
[TBL] [Abstract][Full Text] [Related]
42. The clinicopathological features and prognosis of signet ring cell carcinoma of the esophagus: A 10-year retrospective study in China.
Chen L; Liu X; Gao L; Wang R; Gao D; Bai D
PLoS One; 2017; 12(5):e0176637. PubMed ID: 28486494
[TBL] [Abstract][Full Text] [Related]
43. Primary signet-ring carcinoma (SRC) of the lung: a population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung.
Ou SH; Ziogas A; Zell JA
J Thorac Oncol; 2010 Apr; 5(4):420-7. PubMed ID: 20130484
[TBL] [Abstract][Full Text] [Related]
44. A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy to neoadjuvant therapy for esophagogastric adenocarcinoma.
Zahoor H; Luketich JD; Levy RM; Awais O; Winger DG; Gibson MK; Nason KS
J Thorac Cardiovasc Surg; 2015 Feb; 149(2):538-47. PubMed ID: 25454907
[TBL] [Abstract][Full Text] [Related]
45. Treatment outcomes in patients with signet ring cell carcinoma of the colorectum.
Lee WS; Chun HK; Lee WY; Yun SH; Cho YB; Yun HR; Park SH; Song SY
Am J Surg; 2007 Sep; 194(3):294-8. PubMed ID: 17693269
[TBL] [Abstract][Full Text] [Related]
46. Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma.
Xi M; Hallemeier CL; Merrell KW; Liao Z; Murphy MAB; Ho L; Hofstetter WL; Mehran R; Lee JH; Bhutani MS; Weston B; Maru DM; Komaki R; Ajani JA; Lin SH
Ann Surg; 2018 Aug; 268(2):289-295. PubMed ID: 28628563
[TBL] [Abstract][Full Text] [Related]
47. Using nomograms to predict prognostic factors in young colorectal mucinous and signet-ring cell adenocarcinoma patients.
Wang B; Zeng J; Liu Y
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 30692229
[TBL] [Abstract][Full Text] [Related]
48. Neoadjuvant Therapy for Locally Advanced Esophageal Cancer Should Be Targeted to Tumor Histology.
Stiles BM; Kamel MK; Harrison SW; Rahouma M; Lee B; Nasar A; Port JL; Altorki NK
Ann Thorac Surg; 2019 Jan; 107(1):187-193. PubMed ID: 30278165
[TBL] [Abstract][Full Text] [Related]
49. Advanced gastric carcinoma with signet ring cell histology.
Li C; Kim S; Lai JF; Hyung WJ; Choi WH; Choi SH; Noh SH
Oncology; 2007; 72(1-2):64-8. PubMed ID: 18004078
[TBL] [Abstract][Full Text] [Related]
50. Ordinary colorectal adenocarcinoma vs. primary colorectal signet-ring cell carcinoma: study matched for age, gender, grade, and stage.
Psathakis D; Schiedeck TH; Krug F; Oevermann E; Kujath P; Bruch HP
Dis Colon Rectum; 1999 Dec; 42(12):1618-25. PubMed ID: 10613484
[TBL] [Abstract][Full Text] [Related]
51. The roles of neoadjuvant radiotherapy and lymphadenectomy in the treatment of esophageal adenocarcinoma.
Solomon N; Zhuge Y; Cheung M; Franceschi D; Koniaris LG
Ann Surg Oncol; 2010 Mar; 17(3):791-803. PubMed ID: 19953332
[TBL] [Abstract][Full Text] [Related]
52. Clinicopathological features and outcomes in patients undergoing radical resection for early gastric cancer with signet ring cell histology.
Wang Z; Zhang X; Hu J; Zeng W; Zhou Z
J Visc Surg; 2015 Dec; 152(6):357-61. PubMed ID: 26481069
[TBL] [Abstract][Full Text] [Related]
53. A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer.
Xi M; Liao Z; Deng W; Xu C; Komaki R; Blum M; Hofstetter WL; Ho L; Lin SH
J Thorac Oncol; 2017 Jun; 12(6):1001-1010. PubMed ID: 28351804
[TBL] [Abstract][Full Text] [Related]
54. Sex Disparity in Gastric Cancer: Female Sex is a Poor Prognostic Factor for Advanced Gastric Cancer.
Kim HW; Kim JH; Lim BJ; Kim H; Kim H; Park JJ; Youn YH; Park H; Noh SH; Kim JW; Choi SH
Ann Surg Oncol; 2016 Dec; 23(13):4344-4351. PubMed ID: 27469120
[TBL] [Abstract][Full Text] [Related]
55. P53 and SOX2 Protein Expression Predicts Esophageal Adenocarcinoma in Response to Neoadjuvant Chemoradiotherapy.
van Olphen SH; Biermann K; Shapiro J; Wijnhoven BP; Toxopeus EL; van der Gaast A; Stoop HA; van Lanschot JJ; Spaander MC; Bruno MJ; Looijenga LH
Ann Surg; 2017 Feb; 265(2):347-355. PubMed ID: 28059963
[TBL] [Abstract][Full Text] [Related]
56. Elevated X-linked inhibitor of apoptosis protein (XIAP) expression uncovers detrimental prognosis in subgroups of neoadjuvant treated and T-cell rich esophageal adenocarcinoma.
Schiffmann LM; Göbel H; Löser H; Schorn F; Werthenbach JP; Fuchs HF; Plum PS; Bludau M; Zander T; Schröder W; Bruns CJ; Kashkar H; Quaas A; Gebauer F
BMC Cancer; 2019 May; 19(1):531. PubMed ID: 31151416
[TBL] [Abstract][Full Text] [Related]
57. Predictors of Disease Recurrence and Survival in Esophageal Adenocarcinomas With Complete Response to Neoadjuvant Therapy.
Agoston AT; Zheng Y; Bueno R; Lauwers GY; Odze RD; Srivastava A
Am J Surg Pathol; 2015 Aug; 39(8):1085-92. PubMed ID: 26076061
[TBL] [Abstract][Full Text] [Related]
58. Treatment of clinical T2N0M0 esophageal cancer.
Hardacker TJ; Ceppa D; Okereke I; Rieger KM; Jalal SI; LeBlanc JK; DeWitt JM; Kesler KA; Birdas TJ
Ann Surg Oncol; 2014 Nov; 21(12):3739-43. PubMed ID: 25047477
[TBL] [Abstract][Full Text] [Related]
59. Utility of restaging endoscopic ultrasound after neoadjuvant therapy for esophageal cancer.
Griffin JM; Reed CE; Denlinger CE
Ann Thorac Surg; 2012 Jun; 93(6):1855-9; discussion 1860. PubMed ID: 22516835
[TBL] [Abstract][Full Text] [Related]
60. Should Signet Ring Cell Histology Alter the Treatment Approach for Clinical Stage I Gastric Cancer?
Turgeon MK; Gamboa AC; Rupji M; Lee RM; Switchenko JM; El-Rayes BF; Russell MC; Cardona K; Kooby DA; Staley CA; Maithel SK; Shah MM
Ann Surg Oncol; 2021 Jan; 28(1):97-105. PubMed ID: 32524459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
